Reuters logo
BRIEF-AstraZeneca's lung cancer drug receives full EU approval
April 25, 2017 / 12:36 PM / 5 months ago

BRIEF-AstraZeneca's lung cancer drug receives full EU approval

April 25 (Reuters) - AstraZeneca Plc:

* Tagrisso receives full approval in the EU

* European Commission has granted full marketing authorisation for Tagrisso (osimertinib)

* Grant for treatment of adults with locally-advanced or metastatic epidermal growth factor receptor T790m mutation-positive non-small cell lung cancer

* In March 2017, US Food and Drug Administration granted Tagrisso a conversion from accelerated to full approval

* Warnings and precautions include interstitial lung disease (ILD), keratitis, left ventricular ejection fraction (LVEF) and QTC interval prolongation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below